Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619216 · ClinicalTrials.gov registry record
Myfortic Conversion Trial in OLT Recipients With GI Intolerance
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 31
- Enrollment target
NCT00619216 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 31 participants.
The verdict
NCT00619216 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
Liver transplant patients often require multimodal immunosuppressive therapy to minimize their risk for rejection. In our regimen, MMF (mycophenolate mofetil) is often added to lower the side effects of the calcineurin inhibitors. Unfortunately the literature reports 20% up to as many as 40% of patients have GI intolerance to MMF. At our Center, approximately 30% of patients have intolerance to MMF, thereby mitigating our ability to use this agent. The primary objective of this study is to assess the tolerability of myfortic in combination with Neoral or Tacrolimus as determined by the GSRS (Gastrointestinal Symptom Rating Scale) after conversion from MMF in maintenance liver transplant patients with GI intolerance within 3 months.
Interventions
- DRUG Mycophenolic Acid (Myfortic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619216
The ClinicalTrials.gov registry entry for NCT00619216 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mycophenolic Acid (Myfortic) is the first listed.
NCT00619216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619216 about?
NCT00619216 is a clinical study titled "Myfortic Conversion Trial in OLT Recipients With GI Intolerance". Liver transplant patients often require multimodal immunosuppressive therapy to minimize their risk for rejection. In our regimen, MMF (mycophenolate mofetil) is often added to lower the side effects of the calcineurin inhibitors. Unfortunately the literature reports 20% up to as many as 40% of pati...
What is the current status of trial NCT00619216?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2008-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00619216?
The interventions under investigation include: Mycophenolic Acid (Myfortic) (DRUG).
Who is sponsoring clinical trial NCT00619216?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.